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Reduced-intensity conditioning/nonmyeloablative conditioning regimens are increasingly used in allogeneic
hematopoietic cell transplantation (HCT). Reports have shown CD34þ dose to be important for transplantation
outcome using myeloablative conditioning. The role of CD34þ dose of peripheral blood progenitor cells (PBPC)
has not been previously analyzed in a large population undergoing reduced-intensity conditioning/non-
myeloablative HCT. We studied 1054 patients, ages 45 to 75 years, with acute myeloid leukemia or myelo-
dysplastic syndrome who underwent transplantation between 2002 and 2011. Results of multivariate analysis
showed that PBPC from HLA-matched siblings containing <4  106 CD34þ/kg was associated with higher
nonrelapse mortality (hazard ratio [HR], 2.03; P ¼ .001), overall mortality (HR, 1.48; P ¼ .008), and lower
neutrophil (odds ratio [OR], .76; P ¼ .03) and platelet (OR, .76; P ¼ .03) recovery. PBPC from unrelated donors
with CD34þ dose < 6  106 CD34þ/kg was also associated with higher nonrelapse (HR, 1.38; P ¼ .02) and
overall mortality (HR, 1.20; P ¼ .05). In contrast to reports after myeloablative HCT, CD34þ dose did not affect
relapse or graft-versus-host disease with either donor type. An upper cell dose limit was not associated with
adverse outcomes. These data suggest that PBPC CD34þ doses >4  106 CD34þ/kg and >6  106 CD34þ/kg are
optimal for HLA-matched sibling and unrelated donor HCT, respectively.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTIONedgments on page 1424.
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14.05.021Allogeneic hematopoietic cell transplantation (HCT) for
patients with acute myelogenous leukemia (AML) and mye-
lodysplastic syndrome (MDS) can be curative [1]. In the
setting of myeloablative transplantation, nucleated cell dose
is important for several outcome parameters, including sur-
vival and decreased incidence of graft rejection, infections,Transplantation.
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However, a high CD34þ dose has been associated with
increased risk of acute GVHD and, in some instances, chronic
GVHD [7-10]. Reduced-intensity conditioning and non-
myeloablative regimens are increasingly used for older pa-
tients and for those with pre-existing comorbidities [11-14].
Reduced-intensity/nonmyeloablative conditioning regimens
rely more on the antileukemic effect of the transplanted cells
than on the antileukemic effects of the radiation and
chemotherapy given during conditioning, and peripheral
blood progenitor cells (PBPC) are the predominant graft used
for these transplantations.
Although there are several reports detailing the effect of
CD34 dose on outcomes after HLA-matched sibling trans-
plantations, there are few reports that describe its effect after
unrelated donor transplantations [15,16]. In the largest
report to date, with about 932 recipients of unrelated donor
PBPC transplants, mortality risks were lower with a CD34þ
dose greater than 4.5  106/kg but without increasing GVHD
risks [16]. Although this report included all transplantation
conditioning regimens, the less intense regimens accounted
for only one third of transplantations. A separate analysis of
the less intense conditioning regimens was not performed
and the study period was before 2003. As less intense
conditioning regimens now account for about 40% of allo-
geneic transplantations in adults, we sought to determine
the optimal CD34þ dose for reduced-intensity and non-
myeloablative conditioning regimens that may improve
survival in 1054 patients ages 45 to 75 years with AML or
MDS in a more recent period.
PATIENTS AND METHODS
Data Source
The Center for International Blood and Marrow Transplant Research is a
voluntary working group of more than 450 transplantation centers that
contribute data on consecutive allogeneic and autologous transplantations.
Participating centers are required to report all transplantations consecu-
tively to avoid any selection bias and compliance is monitored. Patients are
followed longitudinally until death or lost to follow-up. All patients pro-
vided written informed consent for data submission and research partici-
pation. The institutional review boards of the Medical College of Wisconsin
and the National Marrow Donor Program approved this study.
Eligibility Criteria
Patients from 45 to 75-years old with AML or MDS who received their
ﬁrst allogeneic transplantation with reduced-intensity/nonmyeloablative
conditioning regimens during the interval between 2002 and 2011 were
included in the analysis. The study population was limited to those with
AML or MDS, the most common indications for allogeneic transplantation in
older patients. All patients received PBPC. The CD34þ dose was reported by
transplantation centers and the dose was determined by the cell processing
laboratories at these centers. Regimens included low-dose total body
irradiation (TBI; 200 cGy), busulfan (8 mg/kg oral or 6.5 mg/kg intrave-
nous), or melphalan 140 mg/m2 [17]. GVHD prophylaxis included tacroli-
mus or cyclosporine withmycophenolate or methotrexate. Patients received
PBPC from HLA-matched siblings (n ¼ 370) or unrelated adult donors HLA
matched at the allele level at HLA-A, -B, -C and -DRB1 (8/8, n ¼ 521) or
mismatched at a single HLA-locus (7/8, n ¼ 163). Patients younger than
45 years were excluded, as most received myeloablative transplantation
conditioning regimens.
Outcomes
The primary outcome of interest was nonrelapse mortality, deﬁned as
death in continuous complete remission. Secondary outcomes examined
included hematopoietic recovery (time to neutrophil recovery,  500/mL for
3 consecutive days, and platelet recovery,  20,000/mL without transfusion
for 7 days), acute GVHD [18], chronic GVHD [19], relapse, and overall
mortality. Relapse was deﬁned as morphologic, molecular, or cytogenetic
evidence of disease recurrence. Death from any cause was considered an
event for overall survival and surviving patients were censored at last
follow-up.Statistical Methods
Exploratory analysis of the effect of CD34þ dose on nonrelapsemortality
was performed separately for HLA-matched sibling and unrelated donor
transplantations. The optimal cut-point for CD34þ dose above and below
which therewere signiﬁcant differences was determined bymaximizing the
partial likelihood from the Cox’s proportional hazards model for nonrelapse
mortality, the primary study endpoint [20]. For HLA-matched sibling
transplantation, survival rates were lower when the CD34þ dose was less
than 4  106/kg. For unrelated donor transplantation, survival rates were
lower when the CD34þ dose was less than 6  106/kg. Therefore, for all
subsequent analyses, the CD34þ dose was considered based on the
threshold dose described above and separate analyses undertaken for
HLA-matched sibling and unrelated donor transplantations. The character-
istics of patients, their disease, and transplantation are shown in Tables 1A
and 1B. Categorical variables were compared using the chi-square test.
The probability of overall survival was calculated using the Kaplan-Meier
estimator [21]. The probabilities of neutrophil and platelet recovery, acute
and chronic GVHD, nonrelapse mortality, and relapse were calculated using
the cumulative incidence method [22].
To study the association between clinical outcomes and CD34þ dose, Cox
regression models [20] were built for acute and chronic GVHD, nonrelapse
mortality, relapse, and overall mortality. Results generated are expressed as
hazard ratio (HR) together with the 95% conﬁdence interval (CI).
The variable of primary interest, CD34þ dose, was held in all steps
of model building. Other variables tested included age (45 to 60
versus > 60 years), sex, performance score (80 versus 90 to 100), recipient
cytomegalovirus serostatus (positive versus negative), body mass index
(normal versus overweight versus obese), disease (AML versus MDS), disease
status (ﬁrst complete remission/refractory anemia versus second remission
versus refractory anemia with excess blasts/relapse), cytogenetic risk (good
versus intermediate versus poor risk), interval from diagnosis to trans-
plantation (<6 versus 6 to 12 versus>12months), conditioning regimen (TBI-
containing versus alkylating agent þ ﬂudarabine þ in vivo T cell depletion
versus alkylating agent þ ﬂudarabine), GVHD prophylaxis (calcineurin
inhibitor þ methotrexate versus calcineurin inhibitor þ mycophenolate),
donor age (18 to 32 versus 33 to 50 versus > 50 years), donor-recipient
HLA match for unrelated donor transplantation only (8/8 versus 7/8
HLA-matched), donor-recipient ABO match (matched versus minor versus
major mismatch), and transplantation period (2002 to 2005 versus 2006 to
2011). The variable of CD34þ dose was retained in all models regardless of
level of signiﬁcance. For other factors, only those associatedwith the outcome
of interest at the 5% level or less were retained in the ﬁnal model. All P values
were 2-sided. Analyses were done using SAS 9.3 (Cary, NC).RESULTS
Patient, Disease, and Transplantation Characteristics
Among the 370 recipients of HLA-matched sibling trans-
plantation (Table 1A), 93 (25%) received PBPC grafts that
contained less than 4  106/kg CD34þ (median CD34þ dose,
5 106/kg). The characteristics of patients who received PBPC
with CD34þ dose less than 4 106/kg and those who received
a higher CD34þ dose were similar, except that those who
received a CD34þ dose less than 4  106/kg were more likely
to report performance scores of 90 or 100, to be obese as
determined by body mass index, and to receive calcineurin
inhibitor with methotrexate for GVHD prophylaxis. Addi-
tionally, male recipients were more likely to receive PBPC
from female donors that contained less than 4106/kg CD34þ
cells. The median follow-up of patients who received grafts
that contained less than 4 106/kg CD34 cells was 50months
and for those who received higher CD34, 60 months.
Among the 687 recipients of unrelated donor trans-
plantation, 281 (41%) received PBPC that contained CD34þ
less than 6  106/kg (median CD34þ dose, 7  106/kg). The
characteristics of the 2 treatment groups were similar except
that patients who received CD34 cells less than 6  106/kg
were more likely to be cytomegalovirus seronegative. Male
recipients were more likely to receive PBPC from female
donors that contained less than 6  106/kg CD34þ cells. The
median follow-up of patients who received grafts with
CD34þ dose less than 6  106/kg CD34 cells was 60 months
and for those who received a higher CD34þ dose, 49 months.
Table 1A
Characteristics of Patients, Their Disease, and Transplantation
Variable CD34þ Dose P
Value
<4  106/kg 4  106/kg
Number 93 277
Age .86
45-60 yr 43 (46%) 131 (47%)
61-75 yr 50 (54%) 146 (53%)
Sex, male 59 (63%) 168 (61%) .63
Recipient CMV serostatus .98
Positive 63 (68%) 188 (68%)
Negative 28 (30%) 84 (30%)
Not reported 2 (2%) 5 (2%)
Performance score .02
90-100 52 (56%) 144 (52%)
80 32 (34%) 124 (45%)
Not reported 9 (10%) 9 (3%)
Body mass index .01
Normal 24 (26%) 98 (35%)
Overweight 34 (37%) 118 (43%)
Obese 35 (38%) 61 (22%)
Disease .30
Acute myeloid leukemia 79 (85%) 222 (80%)
Myelodysplastic syndrome 14 (15%) 55 (20%)
Disease status .02
First complete remission/
refractory anemia
61 (66%) 148 (53%)
Second complete remission 13 (14%) 30 (11%)
Relapse/refractory anemia
with excess blast
19 (20%) 99 (36%)
Cytogenetic risk .47
Good 8 (9%) 32 (12%)
Intermediate 54 (58%) 158 (57%)
Poor 29 (31%) 73 (26%)
Not reported 2 (2%) 14 (5%)
Interval from diagnosis to
transplantation
.41
1-5 mo 44 (47%) 136 (49%)
6-11 mo 24 (26%) 84 (30%)
12 mo 25 (27%) 57 (21%)
Conditioning regimen .78
TBI (200 cGy) þ ﬂudarabine 17 (18%) 63 (23%)
TBI (200 cGy) þ
cyclophosphamide or
busulfan
4 (4%) 13 (5%)
Alkylating agent þ ﬂudarabine
þ ATG
20 (22%) 57 (21%)
Alkylating agent þ ﬂudarabine
without ATG
52 (56%) 144 (52%)
Graft-versus-host disease
prophylaxis
.04
Calcineurin inhibitor þ
methotrexate
57 (61%) 135 (49%)
Calcineurin inhibitor þ
mycophenolate
36 (39%) 142 (51%)
Donor-recipient sex match .03
Female donor/male recipient 35 (38%) 72 (26%)
Other 58 (62%) 205 (74%)
Donor-recipient blood group
ABO match
.53
Matched 60 (65%) 166 (60%)
Minor mismatch 14 (15%) 39 (14%)
Major mismatch 18 (19%) 61 (21%)
Not reported 1 (1%) 11 (4%)
Transplantation period .31
2002-2005 36 (39%) 124 (45%)
2006-2011 57 (61%) 153 (55%)
Follow-up, median (range), mo 50 (12-97) 60 (4-144)
CMV indicates cytomegalovirus; ATG, antithymocyte globulin.
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The effects of CD34þ dose on hematopoietic recovery are
shown in Tables 2A and 2B (Figure 1A,B). For HLA-matched
sibling donor transplantation, PBPC containing less than
4106/kg CD34 cells was associatedwith lower likelihoods ofneutrophil (odds ratio [OR], .76; 95% CI, .60 to .98; P¼ .03) and
platelet (OR, .76; 95% CI, .58 to .98; P ¼ .03) recovery
(Table 2A). For unrelated donor transplantations, hematopoi-
etic recovery was not associated with CD34þ dose (Table 2B).
GVHD
CD34þ dose was not associated with grade 2 to 4 acute
GVHD after HLA-matched sibling or unrelated donor trans-
plantation (Table 2A,B). CD34þ dose was also not associated
with chronic GVHD after HLA-matched sibling trans-
plantations (Table 2A), except when the dose was greater
than 10  106/kg (n ¼ 38). Transplantation of grafts that
contained CD34þ dose greater than 10  106/kg was associ-
ated with lower risks of chronic GVHD compared with grafts
that contained < 4  106/kg (HR, .46; 95% CI, .23 to .89;
P ¼ .02) or 4 to 10  106/kg (HR, .45; 95% CI, .24 to .83;
P ¼ .01). CD34þ dose was not associated with chronic GVHD
after unrelated donor transplantation (Table 2B). We tested
for an effect of higher CD34þ dose (>10  106/kg) and found
none (data not shown).
Relapse and Nonrelapse Mortality
The CD34þ dose was not associated with relapse after
HLA-matched sibling or unrelated donor transplantation
(Table 2A,B). However, CD34þ dose was associated with
nonrelapse mortality risks (Table 2A,B; Figure 2A,B). Trans-
plantation of PBPC from HLA-matched siblings containing
CD34þ less than 4  106/kg was associated with higher
nonrelapse mortality. Similarly, transplantation of PBPC from
unrelated donors containing CD34þ less than 6  106/kg was
associated with higher nonrelapse mortality.
Overall Survival
Transplantation of PBPC from HLA-matched siblings with
CD34þ dose less than 4  106/kg was associated with higher
overall mortality (Table 2A, Figure 3A). CD34þ dose was only
marginally associated with overall mortality after unrelated
donor transplantation (Table 2B, Figure 3B). There were no
differences in causes of death between the 2 CD34þ dose
groups for either donor source. For recipients of HLA-matched
sibling transplants, approximately 50% of deaths were
attributed to recurrent disease and the remaining attributed
to transplantation-related causes. Similarly, for recipients of
unrelated donor transplants, approximately 40% of deaths
were attributed to recurrent disease and the remaining
attributed to transplantation-related causes.
Subset Analysis
The Sorror comorbidity score [23] was ascertained for
patients who underwent transplantation between 2008 and
2011. This score is not available for patients who underwent
transplantation before 2008. One hundred and forty-six
recipients of HLA-matched sibling transplantation were
evaluable and there were no differences in the comorbidity
score between the 2 CD34þ dose groups (P ¼ .70). Two hun-
dred and eighty-two recipients of unrelated donor trans-
plantation were evaluable and there were no differences in
comorbidity score between the 2 CD34þ dose groups (P¼ .43).
Among recipients of HLA-matched sibling transplants, a co-
morbidity score of 2 or 3 was not associated with higher
overall mortality (data not shown). However, in recipients of
unrelated donor transplants, comorbidity scores of 2 and 3 or
higher were associated with higher overall mortality (HR,
1.63; 95% CI, 1.02 to 2.61; P ¼ .04 and HR, 1.75; 95% CI, 1.13 to
2.70; P ¼ .01, respectively), independent of CD34þ dose.
Table 1B
Characteristics of Patients, Their Disease, and Transplantation
Variable CD34þ Dose P Value
<6  106/kg 6  106/kg
Number 281 406
Age .54
45-60 yr 120 (43%) 183 (45%)
61-75 yr 161 (57%) 223 (55%)
Sex, male 185 (66%) 245 (60%) .14
Recipient CMV serostatus .01
Positive 154 (55%) 257 (63%)
Negative 121 (43%) 148 (36%)
Not reported 6 (2%) 1 (<1%)
Performance score .87
90-100 158 (56%) 227 (56%)
80 109 (39%) 155 (38%)
Not reported 14 (5%) 26 (6%)
Body mass index .61
Normal 71 (25%) 116 (29%)
Overweight 108 (38%) 153 (38%)
Obese 102 (36%) 137 (34%)
Disease .82
Acute myeloid leukemia 229 (81%) 328 (81%)
Myelodysplastic syndrome 52 (19%) 78 (19%)
Disease status .66
First complete remission/refractory anemia 140 (50%) 203 (50%)
Second complete remission 54 (19%) 68 (17%)
Relapse/refractory anemia with excess blast 87 (31%) 135 (33%)
Cytogenetic risk .42
Good 8 (9%) 32 (12%)
Intermediate 54 (58%) 158 (57%)
Poor 29 (31%) 73 (26%)
Not reported 2 (2%) 14 (5%)
Interval from diagnosis to transplantation .79
1-5 mo 104 (37%) 158 (39%)
6-11 mo 97 (35%) 136 (33%)
12 mo 78 (28%) 111 (27%)
Not reported 2 (<1%) 1 (<1%)
Conditioning regimen .06
TBI (200 cGy) þ ﬂudarabine 40 (14%) 79 (19%)
TBI (200 cGy) þ cyclophosphamide or busulfan 13 (5%) 28 (7%)
Alkylating agent þ ﬂudarabine þ ATG 113 (40%) 170 (42%)
Alkylating agent þ ﬂudarabine without ATG 115 (41%) 129 (32%)
Graft-versus-host disease prophylaxis .13
Calcineurin inhibitor þ methotrexate 121 (43%) 198 (49%)
Calcineurin inhibitor þ mycophenolate 160 (57%) 208 (51%)
Donor-recipient sex match .002
Female donor/male recipient 63 (22%) 72 (26%)
Other 214 (76%) 205 (74%)
Not reported 4 (1%) 10 (2%)
Donor-recipient blood group ABO match .51
Matched 120 (43%) 154 (38%)
Minor mismatch 69 (25%) 118 (29%)
Major mismatch 91 (33%) 132 (33%)
Not reported 1 (<1%) 2 (<1%)
Donor-recipient HLA-match .60
8/8 HLA-matched 211 (75%) 312 (77%)
7/8 HLA-matched 70 (25%) 94 (23%)
Donor age .12
18-32 yr 102 (36%) 178 (44%)
33-50 yr 138 (49%) 188 (46%)
>50 yr 22 (8%) 21 (5%)
Not reported 19 (7%) 19 (5%)
Transplantation period .32
2002-2005 73 (26%) 92 (23%)
2006-2011 208 (74%) 314 (77%)
Follow-up, median (range), mo 60 (12-101) 49 (4-97)
HLA indicates human leukocyte antigen.
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Published literature support that CD34þ dose is associ-
ated with transplantation outcomes after bone marrow or
mobilized peripheral blood HLA-matched sibling and unre-
lated donor transplantation [2-10,15,16]. However, mostof these reports primarily included recipients of myeloa-
blative transplantation conditioning regimens and bone
marrow graft. An increasing number of reduced-intensity/
nonmyeloablative conditioning regimens for allogeneic
transplantation are being performed, as this treatment is
Table 2A
Results of Multivariate Analysis: HLA-Matched Sibling Transplantation
Risk Factor Hazard Ratio (95% CI) P Value
Neutrophil recovery*
CD34 dose  4  106/kg 1.00
CD34 dose < 4  106/kg .76 (.60-.98) .03
Platelet recoveryy
CD34 dose  4  106/kg 1.00
CD34 dose < 4  106/kg .76 (.58-.98) .03
Grade 2-4 acute GVHDz
CD34 dose  4  106/kg 1.00
CD34 dose < 4  106/kg .98 (.64-1.49) .91
Chronic GVHDx
CD34 dose  4  106/kg 1.00
CD34 dose < 4  106/kg 1.09 (.75-1.58) .65
Nonrelapse mortalityk
CD34 dose  4  106/kg 1.00
CD34 dose < 4  106/kg 2.03 (1.26-3.27) .004
Relapse{
CD34 dose  4  106/kg 1.00
CD34 dose < 4  106/kg 1.06 (.73-1.52) .77
Overall mortality#
CD34 dose  4  106/kg 1.00
CD34 dose < 4  106/kg 1.48 (1.11-1.99) .008
* Adjusted for conditioning regimen. Recovery was less likely with low-
dose irradiation regimens (HR, .61; P ¼ .0002).
y Adjusted for performance score, disease, and transplantation period.
Recovery was less likely with performance scores 80 or lower (HR, .68;
P ¼ .0009), diagnosis of MDS (HR, .64; P ¼ .002), and transplantations be-
tween 2002 and 2005 (HR, .68; P ¼ .0007).
z Adjusted for conditioning regimen and GVHD prophylaxis. Risks were
lower with irradiation-containing (HR, .50; P ¼ .006), nonirradiation regi-
mens with in vivo Tcell depletion (HR, .54; P ¼ .02), and with GVHD pro-
phylaxis that included calcineurin inhibitor with methotrexate (HR, .53;
P ¼ .003).
x Adjusted for conditioning regimen. Lower risks after nonirradiation
regimens with in vivo T cell depletion (HR, .42; P ¼ .0005) compared with
nonirradiation regimens without in vivo T cell depletion.
k Adjusted for disease status at transplantation. Transplantation in
relapse was associated with higher nonrelapse mortality (HR, 1.94;
P ¼ .006).
{ Adjusted for performance score, disease, disease status at trans-
plantation, cytogenetic risk, conditioning regimen, GVHD prophylaxis, and
transplantation period. Risks were higher for those with AML (HR, 1.74;
P ¼ .03), transplantation in relapse (HR, 1.82; P ¼ .001), poor risk cytoge-
netics (HR, 2.03; P ¼ .03), performance scores of 80 or lower (HR, 1.56;
P ¼ .006), nonirradiation regimens with in vivo T cell depletion (HR, 1.93;
P ¼ .0004), calcineurin inhibitor with methotrexate GVHD prophylaxis (HR,
1.83; P ¼ .003), and transplantations performed before 2006 (HR, 1.54;
P ¼ .01).
# Adjusted for performance score, disease status at transplantation, cy-
togenetic risk, and transplantation period. Higher overall mortality for
performance scores of 80 or lower (HR, 1.72; P < .0001), poor risk cytoge-
netic abnormalities (HR, 2.13; P ¼ .002), transplantations in relapse (HR,
1.34; P ¼ .04), and those performed before 2006 (HR, 1.44; P ¼ .008).
Table 2B
Results of Multivariate Analysis: Unrelated Donor Transplantation
Factor Hazard Ratio (95% CI) P Value
Neutrophil recovery*
CD34 dose  6  106/kg 1.00
CD34 dose < 6  106/kg 1.02 (.87-1.19) .81
Platelet recoveryy
CD34 dose  6  106/kg 1.00
CD34 dose < 6  106/kg .87 (.74-1.02) .09
Grade 2-4 acute GVHDz
CD34 dose  6  106/kg 1.00
CD34 dose < 6  106/kg 1.11 (.88-1.41) .39
Chronic GVHDx
CD34 dose  6  106/kg 1.00
CD34 dose < 6  106/kg .87 (.70-1.09) .22
Nonrelapse mortalityk
CD34 dose  6  106/kg 1.00
CD34 dose < 6  106/kg 1.38 (1.06-1.79) .02
Relapse{
CD34 dose  6  106/kg 1.00
CD34 dose < 6  106/kg .96 (.76-1.22) .74
Overall mortality#
CD34 dose  6  106/kg 1.00
CD34 dose < 6  106/kg 1.20 (1.00-1.43) .05
* Adjusted for age, donor-recipient HLA-match, and conditioning
regimen. Recovery was less likely in patients aged less than 60 years (HR,
.84; P ¼ .03), low-dose irradiation regimens (HR, .61; P < .0001), in vivo
T cell depletionwith alkylating agents and ﬂudarabine (HR, .82; P¼ .03), and
7/8 HLA-matched transplantations (HR, .78; P ¼ .007).
y Adjusted for performance score, disease status, time from diagnosis to
transplantation, conditioning regimen, and transplantation period. Recov-
ery was less likely with performance score 80 or lower (HR, .76; P ¼ .002)
and interval from diagnosis to transplantation 6 to 12 months (HR, .78;
P ¼ .01) or longer than 12 months (HR, .72; P ¼ .006) compared with less
than 6 months and transplantation in relapse compared with complete
remission (HR, .80; P ¼ .02). Platelet recovery was more likely with TBI-
containing regimens (HR, 1.43; P ¼ .001) and for transplantations per-
formed after 2005 (HR, 1.28; P ¼ .01).
z Adjusted for body mass index, disease status, and GVHD prophylaxis.
Grade 2 to 4 acute GVHD risks after unrelated donor transplantation were
lower in obese (HR, .72; 95% CI, .64 to .96; P ¼ .03) and overweight (HR, .72;
95% CI, .54 to .96; P ¼ .02) patients compared with those with normal body
mass index, transplantations in second compared with ﬁrst complete
remission (HR, .63; 95% CI, .43 to .90; P¼ .01), and calcineurin inhibitor with
methotrexate compared with mycophenolate GVHD prophylaxis (HR, .58;
95% CI, .45 to .74; P < .0001). Acute GVHD risks were higher for trans-
plantations in relapse or refractory anemia with excess blasts (HR, 1.35; 95%
CI, 1.05 to 1.74; P ¼ .02).
x Adjusted for conditioning regimen and GVHD prophylaxis. Risks were
lower after nonirradiation regimens with in vivo T cell depletion (HR, .54;
P < .0001) and with calcineurin inhibitor and methotrexate GVHD pro-
phylaxis (HR, .64; P ¼ .0007).
k Adjusted for disease status at transplantation, time from diagnosis to
transplantation, and HLA match. Higher nonrelapse mortality risks for
transplantation of grafts from donors who were HLA mismatched to the
patient (HR, 1.47; P ¼ .009) and when the interval from diagnosis to
transplantation was longer than 12 months (HR, 1.76; P ¼ .004). Risks were
lower for transplantations in second complete remission compared with in
ﬁrst complete remission (HR, .43; P ¼ .0004).
{ Adjusted for performance score, body mass index, disease, disease sta-
tus at transplantation, and cytogenetic risk. Risks were higher for those with
AML (HR, 1.61; P ¼ .01), transplantation in relapse (HR, 1.77; P ¼ .001), and
performance scores of 80 or lower (HR, 1.56; P ¼ .0004).
# Adjusted for age and performance score. Higher mortality with per-
formance scores of 80 or lower (HR, 1.38; P ¼ .003) and patients older than
60 years (HR, 1.27; P ¼ .01).
J. Törlén et al. / Biol Blood Marrow Transplant 20 (2014) 1418e14251422now offered to older individuals and those who are unable to
tolerate myeloablative regimens. It is in this group of trans-
plant recipients that the potential effect of CD34þ dose on
transplantation outcomes is not well described. Therefore, in
the current analysis, we assessed the effect of PBPC CD34þ
dose on transplantation outcomes in over 1000 patients with
AML andMDS, the 2 most common indications for allogeneic
transplantation in patients over the age of 45 years. An
important ﬁnding of the current analysis is the independent
predictive value of a higher CD34þ dose for improvements in
survival after HLA-matched and unrelated donor trans-
plantation. Notably, the threshold of CD34þ dose associated
with better survival was lower, at 4  106/kg for
HLA-matched sibling transplantations than for unrelated
transplant recipients, where the threshold was 6  106/kg.
We did not detect additional lower dose thresholds that were
associated with worse survival. Although our ﬁndings tosome extent conﬁrm those reported by others, there are also
notable differences, such as the lack of association between
higher cell dose and disease recurrence [5,15,24]. Our
inability to observe differences in relapse risks may be
explained by differences in regimen intensity between the
current analysis and earlier reports [5,15,24]. The current
analysis is limited to reduced-intensity/nonmyeloablative
regimens with greater reliance on immune modulation and
Figure 1. (A) The incidence of neutrophil recovery after transplantation of
PBPC from HLA-matched siblings. (B) The incidence of neutrophil recovery
after transplantation of PBPC from unrelated donors.
Figure 3. (A) The probability of overall survival after transplantation of PBPC
from HLA-matched siblings. (B) The probability of overall survival after
transplantation of PBPC from unrelated donors.
J. Törlén et al. / Biol Blood Marrow Transplant 20 (2014) 1418e1425 1423graft-versus-leukemia effects and it may not be possible to
identify a CD34þ dose threshold for disease recurrence in this
setting. On the other hand, a large series from the National
Marrow Donor Program, limited to PBPC transplantations for
hematologic malignancy, which included transplantationFigure 2. (A) The incidence of nonrelapse mortality after transplantation of
PBPC from HLA-matched siblings. (B) The incidence of nonrelapse mortality
after transplantation of PBPC from unrelated donors.conditioning regimens of all intensities, also failed to see an
effect of CD34þ on disease recurrence, similar to our ﬁndings.
Further, we were unable to identify an adverse effect of
any upper limit of CD34þ dose on outcomes after both
HLA-matched and unrelated donor transplantations [3,9,10].
It is noteworthy that the CD34þ dose threshold above which
we observed better survival varied by donor source, with a
higher CD34þ requirement for PBPC from unrelated donors.
The observed difference in dose threshold between matched
sibling and unrelated donor transplantations may be attrib-
uted to differences in HLA-matching between donors
and recipients. Although approximately three quarters of
unrelated donor-recipient pairs were HLA-matched at the
allele level at HLA-A, -B, -C, and -DRB1, we did not consider
HLA-match at the DP locus or HLA-match at the low-
expression alleles [25,26]. It is plausible the cell dose
threshold needed to improve survival could be higher with
HLA disparity. A single HLA -locus mismatch at 1 of the high-
expression alleles (A, B, C, or DRB1) was associated with
higher mortality, but this effect was independent of CD34þ
dose. The CD34þ threshold dose of 6  106/kg for unrelated
donor transplantations that we observed is higher than that
reported in the earlier report from the National Marrow
Donor Program [16]. In that report, with 600 recipients of
myeloablative conditioning and 320 recipients of reduced-
intensity/nonmyeloablative conditioning, survival was bet-
ter with PBPC grafts that contained a CD34þ dose greater
than 4.5  106/kg. The observed difference in CD34þ dose
threshold between that report and the current analysis may
be explained by differences in the characteristics of the study
population. Ours is a relatively homogenous populationwith
AML and MDS, all patients were older than 45 years who
received reduced-intensity/nonmyeloablative conditioning
regimens, and almost all underwent transplantation after
2003 and received better HLA-matched grafts.
J. Törlén et al. / Biol Blood Marrow Transplant 20 (2014) 1418e14251424Hematopoietic recovery was better after transplantation
of PBPC grafts with a CD34þ dose greater than 4  106/kg
from HLA-matched siblings. This is not surprising, as better
graft composition is associated with better recovery rates
and fewer graft failures [27].
In the setting of unrelated donor transplantations, we did
not observe an association between CD34þ dose and he-
matopoietic recovery. The lack of association is surprising
but is consistent with the other large report on CD34þ dose
and outcomes after unrelated donor transplantation [16].
The association between CD34þ dose and acute and
chronic GVHD aremixed, with some studies reporting higher
GVHD rates, others lower rates, and several reports that have
failed to show an association [3,5,6,9,15,16,27,28]. We did not
observe differences in acute GVHD rates by CD34þ dose with
either donor source. However, we observed lower rates of
chronic GVHD with PBPC that contained CD34þ dose greater
than 10  106/kg after HLA-matched sibling transplantation
only. This was observed in 38 patients (10% of recipients of an
HLA-matched sibling transplant), a relatively small cohort
warranting further conﬁrmation in larger study population.
It is plausible that grafts containing a low CD34þ dose may
trigger infections, which in turn may trigger acute GVHD.
Reduced-intensity/nonmyeloablative conditioning regimens
are generally associated with higher acute and chronic
GVHD, regardless of donor source. In the absence of an
adverse effect on survival, together with the relatively small
numbers of patients who received very high CD34þ dose, we
conclude there are no speciﬁc advantages to receiving PBPC
that contain a substantially higher dose of CD34þ than the
threshold dose associated with higher survival. Further,
Weisdorf et al. examined the effect of acute and chronic
GVHD in patients with AML and MDS who had survived
disease free for at least 1 year after reduced-intensity/
nonmyeloablative transplantations [29]. Only patients with
a history of both acute and chronic GVHD experienced lower
recurrence, but higher nonrelapse mortality negated any
potential beneﬁcial effects from GVHD. We also tested for an
effect of CD34þ dose and GVHD in the setting of in vivo
T celledepleted transplantations and found none.
The current analyses used data collected by a trans-
plantation registry. Consequently, CD34þ dose was not
measured in a central laboratory but at individual trans-
plantation centers and varying laboratory standards may
have inﬂuenced, at least in part, some of our observations.
Another limitation is that we were unable to test for an effect
of the Sorror comorbidity index in all patients. These data
were available for only about one half of the patients reported
in the current analyses, as this comorbidity index was not
routinely assessed before 2008. However, in subset analyses,
a higher comorbidity index was associated with higher
mortality, independent of CD34þ dose for recipients of un-
related donor transplantation. Our inability to detect a sig-
niﬁcant effect for recipients of HLA-matched sibling
transplants may be attributed to a relatively small sample size
of 146. Importantly, recipients of HLA-matched sibling
transplants were equally likely to report worse comorbidity
score (2 or more) in both CD34þ dose groups. Although we
controlled for known risk factors associated with trans-
plantation outcomes and ensured the effect of these risk
factors were independent of the effect of CD34þ dose, there
may be several unknown or unmeasured factors that inﬂu-
enced outcomes. Nevertheless, we were able to show the
independent effect of higher CD34þ dose on nonrelapse and
overall mortality after reduced-intensity/nonmyeloablativeconditioning HLA-matched sibling and unrelated donor
transplantation in a relatively homogenous population. The
data offer the opportunity to establish standards for PBPC
collection from related and unrelated donors when contem-
plating reduced-intensity conditioning transplantation for
older patients with AML or MDS, so that some of the excess
mortality associated with allogeneic transplantation may be
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